Description
Nobazit Pharmacodynamics
Enisamy iodide is an antiviral agent, a derivative of isonicotinic acid.
Effectively suppresses the effect of influenza viruses and other pathogens of acute respiratory viral infections (ARI) due to the direct (inhibitory) effect on the process of virus penetration through the cell membrane.
It has interferonogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times.
Increases the body’s resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.
Indications
Treatment of influenza and other acute respiratory infections in adults and adolescents, including as part of combination therapy.
Contraindications .
Hypersensitivity to any of the components of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Sucrose/isomaltase deficiency, fructose intolerance. Children under 12 years of age, pregnancy, breast-feeding. Allergic reactions regardless of the nature of the allergen in the history. Severe organic liver and kidney damage.
Caution
Patients with thyroid problems, especially with hyperthyroidism.
Administration during pregnancy
And during the breast-feeding period
Contraindicated for use during pregnancy and breast-feeding.
Directions for use and dosages.
- Treatment should begin at the first signs of the disease. If after 3 days of treatment no improvement or aggravation of symptoms or appearance of new symptoms, consult a doctor. Use the drug only according to the indications, method of administration and dosage indicated in the instructions.
- NOBASIT® is taken orally after meals without chewing.
- Maximal single dose is 1000 mg, daily dose – 2000 mg.
- Adults: 500 mg 3 times per day. The recommended course of treatment is from 5 to 7 days.
- Children from 12 years of age – 250 mg 3 times a day for 7 days.
